IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
This image was generated by AI and may not depict real events.
IGC Pharma has received authorization in Colombia to conduct research involving psilocybin for treating neuropsychiatric symptoms in dementia. The company is evaluating psilocybin's potential applications alongside its ongoing Phase 2 CALMA trial for agitation associated with Alzheimer's disease.
IGC Pharma, a clinical-stage biotechnology company, has received authorization in Colombia to synthesize and conduct development activities involving psilocybin. The authorization allows the company to evaluate psilocybin's potential applications in neuropsychiatric symptoms associated with dementia, such as depression and anxiety. Neuropsychiatric symptoms affect about 80% of Alzheimer's patients, representing a significant market opportunity. IGC Pharma's lead candidate, IGC-AD1, is advancing through a Phase 2 clinical trial targeting agitation. The company's CALMA trial has reached approximately 80% patient enrollment and is nearing completion. The psilocybin authorization provides a capital-efficient platform to evaluate emerging therapeutic approaches in neuropsychiatric disorders.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.